One of the proteins on the virus - located on the characteristic COVID spike - has a component called the receptor-binding domain, or RBD, which is its "Achilles heel." That is, he said, antibodies against this part of the virus have the potential to the neutralize the virus.
Researchers at the University of Basel have developed a precisely controllable system for mimicking biochemical reaction cascades in cells. Using microfluidic technology, they produce miniature polymeric reaction containers equipped with the desired properties. This 'cell on a chip' is useful not only for studying processes in cells, but also for the development of new synthetic pathways for chemical applications or for biological active substances in medicine.
A huge global research effort is taking place to bring a fast-tracked COVID-19 vaccine to the market but there is concern that certain countries may prioritise their own population's access to any vaccines developed. New RAND Europe research shows that if some countries are unable to obtain vaccines owing to vaccine nationalism it could cost the global economy up to $1.2 trillion per year in GDP terms.
Women with epilepsy who take the antiseizure drug valproic acid while pregnant are at more than double the risk of having children with autism spectrum disorder and nearly double the risk of having children with attention deficit hyperactivity disorder (ADHD), according to a study in the October 28, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.
In 2003, the painkiller paracetamol became available in Switzerland in tablets with a higher dose of the active ingredient. This correlates with an increase in cases of paracetamol poisoning in the country, as a data analysis by ETH researchers shows.
Scientists at Scripps Research have uncovered a potential new strategy for treating eye diseases that affect millions of people around the world, often resulting in blindness.
An international team of researchers led by Cleveland Clinic's Lerner Research Institute has performed for the first time a wide-scale characterization of missense variants from 1,330 disease-associated genes. Published in Proceedings of the National Academy of Sciences, the study identifies features associated with pathogenic and benign variants that reveal the effects of the mutations at a molecular level.
Study in Nature Medicine shows superior outcomes for patients in LLS's paradigm-shifting beat AML clinical trial.
Scientists from the iMolecule group at Skoltech developed BiteNet, a machine learning (ML) algorithm that helps find drug binding sites, i.e. potential drug targets, in proteins. BiteNet can analyze 1,000 protein structures in 1.5 minutes and find optimal spots for drug molecules to attach.
A new study led by researchers at Queen Mary University of London provides potential novel biomarkers for predicting patient responsiveness to disease modifying anti-rheumatic drugs (DMARDs).